S114of a broader randomized controlled trial.It included 44 MM adult patients, who received chemotherapy or biological therapy at Carmel Medical Center in Isreal.Once they sign a consent form, they were randomized into two groups (23 Intervention, 21 Control).In the intervention group, the pharmacist examined the patient's entire medical treatment and sent recommendations to the family physician and hematoocologist.On the day of the treatment, the pharmacist has met with the patient and provided him/her with a discharge counseling in addition to close supervision for 4 months during the treatment period.The control group was treated without increased pharmacological intervention.The data collection phase had ended one month after intervention period.The control group data was examined after the end of treatment to prevent ethical dilemmas.The variables that were examined are compliance, ADR and balancing medical incidences.Results: Intervention group: it was found that 65.2% of the patients did not take their medication according to the manufacturer's instructions, 8.7% took medication that were not registered in their medical fi le, 30.4% took medication at a different dose than recommended, 56% of patients had poor compliance to one or more prophylactic treatments.90 recommendations were sent to the hemato-oncologist -79 (87.7%) were accepted.57 recommendations were sent to the family physicians and 40 (70%) of them were accepted.During the follow-up period, an improvement of 100% in adherence to the manufacturer's instructions, 100% of the medications were registered in the patient's fi le and the response to prophylactic treatment increased to 96%.Among the patients in the intervention group, there was an improvement in the indices of diabetes balance (13%), LDL (34%), vitamin D (30%) and GFR (34%).This is in comparison with an improvement of 4.7%, 9.5%, 23% and a 14% in the control group.During the follow-up period in the intervention group 7 cases of ADR were reported compared to 19 cases in the control group.Conclusion: We found that integrating of a designated pharmacist as part of the hemato-oncology department during the Covid-19 pandemic had high positive effect on the quality and sequence of drug treatment and reduced the incidence of ADR "Crisis is also an opportunity" -integrating a designated pharmacist should be considered even in routine days.

Multiple myeloma is a malignancy of plasma cells, which is highly associated with immune suppression. Consistent with this, reports of outcomes of COVID-19 infection in patients with multiple myeloma show higher rates of severe disease than in the general population.1,2 Protection of this vulnerable patient group from COVID-19 infection is crucial but response to the new vaccines in patients with multiple myeloma is unknown. A recent report showing low anti-SARS-CoV-2 IgG response to the Pfizer vaccine in patients with cancer included 38 patients with haematological malignancies (nine patients with multiple myeloma) and showed only a 13% response rate, raising concerns that multiple myeloma might be associated with attenuated vaccine response.